Comparison · NCT03150173-fa55cfff
O-BMT (Onsite Treatment) vs Enhanced Referral: Buprenorphine Adherence (Self-reported)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. O-BMT (Onsite Treatment) vs Enhanced Referral: Buprenorphine Adherence (Self-reported). Trial comparisons, record NCT03150173-fa55cfff. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03150173-fa55cfff
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.464 | 0.295 | 0.642 | wilson | |
| Risk in group 2 | 0.382 | 0.239 | 0.55 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0819 | -0.156 | 0.31 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.21 | 0.677 | 2.18 | log | |
| Odds ratio, group 1 over group 2 | 1.4 | 0.507 | 3.86 | log | |
| Number needed to treat, for one more participant with the outcome on O-BMT (Onsite Treatment) than on Enhanced Referral | 12.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | O-BMT (Onsite Treatment) | Over 2 weeks at the syringe-exchange program, participants in the O-BMT arm will see a buprenorphine provider twice, receive weekly blister packs of medication, and then their care will be transferred to a community health center for maintenance buprenorphine treatment~Onsite treatment: Participants will see a buprenorphine treatment provider who will assess for clinical criteria for opioid use disorder and write a prescription for buprenorphine treatment, which will be filled in a community pharmacy.~Buprenorphine: all participants will receive buprenorphine | 13 | 28 | OG000 |
| Group 2 | Enhanced Referral | In the control arm, participants will receive enhanced referral to a community health center for maintenance buprenorphine treatment~Enhanced referral: Participants will receive an expedited appointment at a community health center for evaluation for buprenorphine treatment~Buprenorphine: all participants will receive buprenorphine | 13 | 34 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- POST_HOC
- Title
- Buprenorphine Adherence (Self-reported)
- Description
Buprenorphine Adherence (self-reported), defined as meeting the primary outcome of buprenorphine engagement and self-reporting buprenorphine use at 30 days, was assessed as a composite measure for sensitivity analysis. The number of participants who both maintained an active buprenorphine prescription at 30 days after randomization, based on a dichotomous (i.e., Yes/No) measure, AND self-reported having taken buprenorphine on 1 or more days during the 30-day period were tabulated. Data are summarized by study arm.
- Time frame
- 30 days after randomization
- Population
- Self-reported buprenorphine use data was unable to be collected from 20 participants in the onsite buprenorphine treatment (O-BMT) study arm and 15 participants in the Enhanced referral study arm.
Source ClinicalTrials.gov
Trial
- Title
- Onsite Buprenorphine Treatment at Syringe Exchange Programs
- NCT number
- NCT03150173
- Phases
- PHASE2
- Conditions
- Opiate Addiction
- Interventions
- Onsite treatment, Enhanced referral, Buprenorphine
- Lead sponsor
- Montefiore Medical Center
- Results first posted
- 2025-01-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03150173?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03150173-fa55cfff